ZYNE — Zynerba Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
Brief: Zynerba Pharmaceuticals Presents Positive Data From Phase 2 Inspire Trial In 22Q11.2 Deletion Syndrome At The National Organization For Rare Disorders (Nord) Rare Diseases And Orphan Products Breakthrough Summit
Brief: Zynerba Pharmaceuticals Announces Issuance Of New U.S. Patent For Zygel
Brief: Zynerba Pharmaceuticals reports Q2 results
Brief: Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement For Up To $20 Million With Lincoln Park Capital
U.S. STOCKS ON THE MOVE-Moderna Inc, Nike Inc, Mustang Bio
U.S. STOCKS ON THE MOVE-Kraft Heinz Co, Coinbase, Altria Group
U.S. STOCKS ON THE MOVE-Athira Pharma, U.S. Well Services, Revlon
U.S. STOCKS ON THE MOVE-Dow, Boeing, Revlon, U.S. Well Services
Zynerba rises on positive data from genetic disorder trial
Brief: Zynerba Pharmaceuticals Announces Positive Top Line Results From Open-Label Phase 2 Inspire Trial Of Zygel
Brief: Zynerba Pharmaceuticals Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
Zynerba Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results And Operational Highlights
Zynerba Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Zynerba Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results And Operational Highlights
Brief: Zynerba Pharmaceuticals Announces Completion Of Enrollment In Phase 2 Trial Of Zygel
Brief: Zynerba Pharmaceuticals Announces Planned Retirement Of Suzanne Hanlon And Appoints Albert P. Parker As Chief Legal Officer
Brief: Zynerba Pharmaceuticals Inc - Plans To Focus Development Of Zygel In FXS, ASD and 22q
Brief: Zynerba Pharmaceuticals Announces Issuance Of New Patent In EU For Zygel